Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini GReumatismo 2009[Apr]; 61 (2): 107-17OBJECTIVE: To evaluate the clinical response after switching to another TNFalpha antagonist in patients with rheumatoid arthritis (RA) and provide a review of the literature on this topic. METHODS: In this ongoing, longitudinal, observational study we have prospectively collected data of patients starting biological treatments since 2000. The present analysis is restricted to RA patients who switched to another anti-TNFalpha due to lack of efficacy (LaE), loss of efficacy (LoE), or adverse events (AEs) by the end of December 2007. Disease activity score (ESR-based DAS28) was calculated and the clinical response (none, moderate, good) was evaluated according to the European League Against Rheumatism (EULAR) criteria. Clinical remission (DAS28 <2.6) and low disease activity (DAS28 |Adalimumab[MESH]|Adolescent[MESH]|Adult[MESH]|Aged[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antirheumatic Agents/administration & dosage/*therapeutic use[MESH]|Arthritis, Rheumatoid/blood/diagnosis/*drug therapy[MESH]|Biomarkers/blood[MESH]|Blood Sedimentation[MESH]|C-Reactive Protein/metabolism[MESH]|Disease Progression[MESH]|Dose-Response Relationship, Drug[MESH]|Drug Therapy, Combination[MESH]|Etanercept[MESH]|Female[MESH]|Humans[MESH]|Immunoglobulin G/therapeutic use[MESH]|Infliximab[MESH]|Male[MESH]|Medical Records[MESH]|Middle Aged[MESH]|Prospective Studies[MESH]|Quality of Life[MESH]|Receptors, Tumor Necrosis Factor/therapeutic use[MESH]|Severity of Illness Index[MESH]|Surveys and Questionnaires[MESH]|Treatment Outcome[MESH]|Tumor Necrosis Factor-alpha/*antagonists & inhibitors[MESH] |
